Metastatic hormone-sensitive prostate cancer (mHSPC) refers to prostate cancer that has spread beyond the prostate to distant sites (e.g., bones, lymph nodes, or organs) and still responds to androgen deprivation therapy (ADT). At this stage, the cancer remains dependent on testosterone for growth and can be effectively suppressed by lowering androgen levels.

Patients typically present with widespread disease at diagnosis or progress from earlier stages. The standard of care includes ADT combined with additional systemic therapy such as docetaxel chemotherapy, or newer androgen receptor pathway inhibitors like abiraterone, enzalutamide, or apalutamide, depending on disease volume, symptoms, and patient health. The goal is to delay progression to castration-resistant disease, control symptoms, and improve overall survival.